CD274 and neoplasm: Possibly they may become validated biomarkers, helping the clinician to decide whether sufficient T-cells have infiltrated the tumor tissue for a PD1-/PD-L1 checkpoint inhibitor, or whether additional immunological strategies are indicated, such as those that increase T-cell priming, proliferation and penetration into the tumor tissue.